Next growth phase for Neogen Chemicals to emanate from pharma venture: ICICI Securities
Chemical

Next growth phase for Neogen Chemicals to emanate from pharma venture: ICICI Securities

Both phase 1, 2 expansion at Dahej would expand organic chemical capacity by 3x with a capex of Rs 130 crore.

  • By ICN Bureau | June 02, 2021

Neogen Chemicals reported topline growth of 13% YoY to Rs 92.7 crore against our expectation of Rs 87.1 crore. The growth was driven by higher growth in the inorganic chemical segment (up 31% YoY) largely on account of better volume growth. Revenue from organic chemical was up 7% YoY to Rs 72 crore.

Growth from organic chemical segment remained subdued owing to capacity constraint. OPM for the quarter expanded 80 bps YoY to 20% leading to EBITDA growth of 17% YoY to Rs 18.5 crore vs. our estimate of Rs 17.2 crore. Gross margins expanded 386 bps YoY, 196 bps QoQ to 43.5%, largely on account of higher realisation and better product mix. Lower taxes (30% vs. 35% in Q4FY20) boosted bottomline growth, which was up 28% YoY to Rs 9.3 crore against our estimate of Rs 8.4 crore.

New capacity to drive incremental growth for organic chemical

Both phase 1, 2 expansion at Dahej would expand organic chemical capacity by 3x with a capex of Rs 130 crore. This would translate into incremental revenue of Rs 350-375 crore at peak utilisation against overall revenues of Rs 306 crore currently. We expect the Dahej facility to largely cater to the custom synthesis opportunity with the Vadodara plant catering to advanced intermediates market. Given both these segments have better gross margins compared to the base business, increase in the share of these segments is likely to expand group gross margins and, thereby, OPM and return ratios.

WC cycle to improve, going forward, thereby FCF

Since Neogen is working on many organic molecules and size of the same is materially lower, it has to keep large WIP inventory to curb manufacturing cycle time. Going forward, with an increase in custom synthesis deliveries and garnering large custom synthesis contracts as witnessed recently, the company can keep dedicated glass lined reactors. Thus, WIP inventories can be restricted significantly. Further, higher bromine consumptions could lead to more bargaining power for Neogen, which can lift the payable cycle. This would improve cash conversion cycle and thereby FCF.

Valuation & Outlook

Since the Dahej capacity would largely cater to the custom synthesis opportunity, we expect gross margins of the business to expand considerably in the years to come given that custom synthesis should have a superior margin profile than the base business.

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2024, 11-12 July 2024, Mumbai

Other Related stories

Startups

Petrochemical

Energy

Digitization